Compass Therapeutics: A Promising, But Shrinking, Window Of Opportunity (NASDAQ:CMPX)
· seekingalpha.com
Compass Therapeutics faces a major setback after tovecimig failed to show an overall survival benefit in biliary tract cancer. Read more on CMPX stock here.
I am now a contributor to Total Pharma Tracker, where you can join me for discussions, get my follow-ups on ideas, and specifically request ideas to explore. It...